Chongqing Zhifei Biological Products Co Ltd
SZSE:300122

Watchlist Manager
Chongqing Zhifei Biological Products Co Ltd Logo
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Watchlist
Price: 27.59 CNY -2.02% Market Closed
Market Cap: 66.2B CNY
Have any thoughts about
Chongqing Zhifei Biological Products Co Ltd?
Write Note

Chongqing Zhifei Biological Products Co Ltd
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Chongqing Zhifei Biological Products Co Ltd
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Gross Profit
ÂĄ9.2B
CAGR 3-Years
-11%
CAGR 5-Years
18%
CAGR 10-Years
34%
Beigene Ltd
HKEX:6160
Gross Profit
ÂĄ14.7B
CAGR 3-Years
108%
CAGR 5-Years
67%
CAGR 10-Years
N/A
Innovent Biologics Inc
HKEX:1801
Gross Profit
ÂĄ6.1B
CAGR 3-Years
12%
CAGR 5-Years
82%
CAGR 10-Years
N/A
Akeso Inc
HKEX:9926
Gross Profit
ÂĄ4.4B
CAGR 3-Years
N/A
CAGR 5-Years
335%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Gross Profit
ÂĄ4.5B
CAGR 3-Years
34%
CAGR 5-Years
45%
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Gross Profit
ÂĄ2.7B
CAGR 3-Years
61%
CAGR 5-Years
57%
CAGR 10-Years
N/A
No Stocks Found

Chongqing Zhifei Biological Products Co Ltd
Glance View

Market Cap
66B CNY
Industry
Biotechnology

Chongqing Zhifei Biological Products Co., Ltd., nestled in the fast-paced city of Chongqing, embodies the nexus between innovative biotechnology and practical healthcare solutions. Founded amidst the booming biotech wave, Zhifei has steadily evolved into a substantial player in the vaccine and biopharmaceutical sector. The company’s core operations revolve around the research, development, production, and sales of vaccines and medical diagnostics, ensuring it caters to the surging demand for advanced healthcare solutions both domestically and internationally. Its product line spans from vaccines aimed at combating infectious diseases to diagnostic tools that aid in addressing public health challenges. Moreover, with a robust R&D wing, Zhifei continuously thrives on innovation, channeling significant investments into developing new vaccines that meet the changing needs of global health landscapes. Zhifei’s business model is tightly interwoven with the fabric of healthcare infrastructure, where its profitability hinges not just on product sales but also on strategic collaborations and licenses. Engaging in partnerships with other global pharmaceutical giants and research entities, Zhifei amplifies its market reach and technological prowess. It navigates through the intricacies of regulatory approvals and market distribution with a balanced approach through joint ventures and distribution agreements, which enhance its footprint in regions with burgeoning healthcare needs. Through a lens of sustainable growth, the company marries its entrepreneurial spirit with operational excellence, thus sustaining its ascendancy in the biopharma industry, while contributing to public health improvements worldwide.

Intrinsic Value
46.72 CNY
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Chongqing Zhifei Biological Products Co Ltd's Gross Profit?
Gross Profit
9.2B CNY

Based on the financial report for Sep 30, 2024, Chongqing Zhifei Biological Products Co Ltd's Gross Profit amounts to 9.2B CNY.

What is Chongqing Zhifei Biological Products Co Ltd's Gross Profit growth rate?
Gross Profit CAGR 10Y
34%

Over the last year, the Gross Profit growth was -37%. The average annual Gross Profit growth rates for Chongqing Zhifei Biological Products Co Ltd have been -11% over the past three years , 18% over the past five years , and 34% over the past ten years .

Back to Top